Reduced amyloid-A-degrading activity in serum in amyloidosis associated with rheumatoid arthritis

Insights

Serum

Area of Science:

  • Biochemistry
  • Immunology
  • Rheumatology

Background:

  • Rheumatoid arthritis (RA) can lead to amyloidosis.
  • Amyloid A (AA) fibril deposition is a hallmark of AA amyloidosis.
  • Understanding the degradation of AA fibrils is crucial for disease management.

Purpose of the Study:

  • To investigate the serum's capacity to degrade amyloid A fibrils.
  • To compare this activity in patients with and without rheumatoid arthritis-associated amyloidosis.
  • To identify factors influencing amyloid A fibril degradation.

Main Methods:

  • Radial diffusion method was employed.
  • Fibrillar amyloid A protein was used as a substrate.
  • Serum samples from patients with amyloidosis, RA without amyloidosis, and healthy controls were analyzed.

Main Results:

  • Serum amyloid A (AA) fibril degrading activity was significantly lower in patients with RA and amyloidosis compared to RA patients without amyloidosis and healthy controls.
  • Elevated alpha 1-antitrypsin concentrations were observed in both patient groups.
  • Alpha 1-antitrypsin inhibited AA fibril degrading activity, showing a negative correlation with activity levels.

Conclusions:

  • Reduced amyloid A fibril degrading activity in patients with rheumatoid arthritis-associated amyloidosis is attributed to inhibition, not enzyme deficiency.
  • Alpha 1-antitrypsin is identified as a key inhibitor of amyloid A fibril degradation in serum.
  • These findings suggest potential therapeutic targets for managing amyloidosis.